Amundi Raises Stock Position in LivaNova PLC $LIVN

Key Points

• Amundi increased its stake in LivaNova PLC by 7.2%, owning a total of 196,435 shares worth approximately $7.36 million.
• Wall Street analysts have largely upgraded their ratings for LivaNova, with a consensus target price of $59.71 and one analyst even giving it a "Strong Buy" rating.
• LivaNova reported earnings of $1.05 per share, significantly surpassing expectations and reflecting a 10.6% increase in quarterly revenue year-over-year.

Amundi raised its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 7.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 196,435 shares of the company's stock after purchasing an additional 13,142 shares during the period. Amundi owned 0.36% of LivaNova worth $7,362,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LIVN. Nuveen LLC acquired a new position in shares of LivaNova during the 1st quarter worth about $30,954,000. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of LivaNova by 100.7% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock valued at $39,398,000 after acquiring an additional 503,350 shares during the last quarter. LSV Asset Management lifted its position in shares of LivaNova by 278.3% in the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock valued at $17,224,000 after acquiring an additional 322,598 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of LivaNova by 13.5% in the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after acquiring an additional 316,993 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of LivaNova by 146.1% during the first quarter. Wellington Management Group LLP now owns 472,843 shares of the company's stock worth $18,573,000 after purchasing an additional 280,718 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Trading Down 0.9%

Shares of LIVN traded down $0.50 during trading on Tuesday, reaching $54.93. 580,674 shares of the company traded hands, compared to its average volume of 554,659. The stock has a 50-day simple moving average of $50.19 and a 200-day simple moving average of $44.26. The stock has a market cap of $3.00 billion, a PE ratio of -14.12 and a beta of 0.97. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $58.91. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. During the same quarter last year, the company posted $0.93 EPS. The firm's quarterly revenue was up 10.6% on a year-over-year basis. On average, analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research report on Tuesday, May 20th. Barclays increased their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.